The DOI matches its Crossref record.
Neutralization of TGF-β by Anti-TGF-β Antibody Attenuates Kidney Hypertrophy and the Enhanced Extracellular Matrix Gene Expression in STZ-Induced Diabetic Mice
Abstract
Diabetic nephropathy is characterized by renal hypertrophy, thickening of basement membranes, and accumulation of extracellular matrix in the glomerular mesangium and the interstitium. Our previous investigations have shown that high glucose concentration increases transforming growth factor (TGF)-β1 mRNA in mesangial and proximal tubule cells and that treatment with anti-TGF-β antibody results in prevention of the effects of high glucose on cell growth (e.g., induction of cellular hypertrophy) and the stimulation of collagen biosynthesis. We evaluated in vivo the functional role of the renal TGF-β system in diabetic kidney disease by treatment of streptozotocin-induced diabetic mice with either a neutralizing monoclonal antibody against TGF-β1, -β2, and -β3 (αT) or nonimmune murine IgG for 9 days. Diabetic mice given IgG demonstrated total kidney and glomerular hypertrophy, significantly elevated urinary TGF-β1 protein, and increased mRNAs encoding TGF-β1, type II TGF-β receptor, α1(IV) collagen, and fibronectin. Treatment of diabetic mice with αT prevented glomerular hypertrophy, reduced the increment in kidney weight by ∼ 50%, and significantly attenuated the increase in mRNA levels without having any effect on blood glucose. The antibody was without significant effect on mRNA levels in nondiabetic mice. This is the first demonstration that the early characteristic features of diabetic renal involvement, which include hypertrophy and increased matrix mRNAs, are largely mediated by increased endogenous TGF-β activity in the kidney and that they can be significantly attenuated by treatment with neutralizing anti-TGF-β antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
Ziyadeh, F. N., Hoffman, B. B., Han, D. C., Iglesias-de la Cruz, M. C., Hong, S. W., Isono, M., Chen, S., McGowan, T. A., & Sharma, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120055097 · Cited by 907
Self-citationMechanisms of Tubulointerstitial Fibrosis
Zeisberg, M., & Neilson, E. G. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010080793 · Cited by 868
A Glimpse of Various Pathogenetic Mechanisms of Diabetic Nephropathy
Kanwar, Y. S., Sun, L., Xie, P., Liu, F.-Y., & Chen, S. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092150 · Cited by 775
Vascular complications in diabetes mellitus: the role of endothelial dysfunction
Schalkwijk, C. G., & Stehouwer, C. D. A. (2005) · Clinical Science · doi:10.1042/cs20050025 · Cited by 657
Gilbert, R. E., & Cooper, M. E. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00721.x · Cited by 649
Relationship between Oxidative Stress and Inflammatory Cytokines in Diabetic Nephropathy
Elmarakby, A. A., & Sullivan, J. C. (2012) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00218.x · Cited by 641
Laping, N. J., Grygielko, E., Mathur, A., Butter, S., Bomberger, J., Tweed, C., Martin, W., Fornwald, J., Lehr, R., Harling, J., et al. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.1.58 · Cited by 635
Wendt, T. M., Tanji, N., Guo, J., Kislinger, T. R., Qu, W., Lu, Y., Bucciarelli, L. G., Rong, L. L., Moser, B., Markowitz, G. S., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63909-0 · Cited by 600
Self-citationTGF-β and fibrosis in different organs — molecular pathway imprints
Pohlers, D., Brenmoehl, J., Löffler, I., Müller, C. K., Leipner, C., Schultze-Mosgau, S., Stallmach, A., Kinne, R. W., & Wolf, G. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.06.004 · Cited by 576
Crosstalk between fibroblasts and inflammatory cells
Van Linthout, S., Miteva, K., & Tschope, C. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu062 · Cited by 569
Functional and Structural Changes in the Kidney in the Early Stages of Obesity
HENEGAR, J. R., BIGLER, S. A., HENEGAR, L. K., TYAGI, S. C., & HALL, J. E. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1261211 · Cited by 549
Koya, D., Jirousek, M. R., Lin, Y. W., Ishii, H., Kuboki, K., & King, G. L. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119503 · Cited by 536
Therapeutic Potential of Nrf2 Activators in Streptozotocin-Induced Diabetic Nephropathy
Zheng, H., Whitman, S. A., Wu, W., Wondrak, G. T., Wong, P. K., Fang, D., & Zhang, D. D. (2011) · Diabetes · doi:10.2337/db11-0807 · Cited by 507
The role of protein kinase C activation and the vascular complications of diabetes
DASEVCIMEN, N., & KING, G. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.04.016 · Cited by 494
Platelet activation in type 2 diabetes mellitus
Ferroni, P., Basili, S., Falco, A., & Davì, G. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00836.x · Cited by 493
Molecular mechanisms of diabetic renal hypertrophy
Wolf, G., & Ziyadeh, F. N. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00590.x · Cited by 472
Self-citationMediators of Diabetic Renal Disease: The Case for TGF-β as the Major Mediator
Ziyadeh, F. N. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000093460.24823.5b · Cited by 463
Self-citationAMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function
Dugan, L. L., You, Y.-H., Ali, S. S., Diamond-Stanic, M., Miyamoto, S., DeCleves, A.-E., Andreyev, A., Quach, T., Ly, S., Shekhtman, G., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66218 · Cited by 456
Self-citationKolm-Litty, V, Sauer, U., Nerlich, A., Lehmann, R., & Schleicher, E. D. (1998) · Journal of Clinical Investigation · doi:10.1172/jci119875 · Cited by 430
KOYA, D., HANEDA, M., NAKAGAWA, H., ISSHIKI, K., SATO, H., MAEDA, S., SUGIMOTO, T., YASUDA, H., KASHIWAGI, A., WAYS, D. K., et al. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.3.439 · Cited by 427
Partial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation
Horan, G. S., Wood, S., Ona, V., Li, D. J., Lukashev, M. E., Weinreb, P. H., Simon, K. J., Hahm, K., Allaire, N. E., Rinaldi, N. J., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-805oc · Cited by 420
RISER, B. L., DENICHILO, M., CORTES, P., BAKER, C., GRONDIN, J. M., YEE, J., & NARINS, R. G. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v11125 · Cited by 388
Murphy, M., Godson, C., Cannon, S., Kato, S., Mackenzie, H. S., Martin, F., & Brady, H. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.9.5830 · Cited by 385
Sun, M., Chen, M., Dawood, F., Zurawska, U., Li, J. Y., Parker, T., Kassiri, Z., Kirshenbaum, L. A., Arnold, M., Khokha, R., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.643585 · Cited by 383
Schrijvers, B. F., De Vriese, A. S., & Flyvbjerg, A. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0018 · Cited by 353
TGF-β in Renal Injury and Disease
Böttinger, E. P. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.02.009 · Cited by 339
Pirfenidone for Diabetic Nephropathy
Sharma, K., Ix, J. H., Mathew, A. V., Cho, M., Pflueger, A., Dunn, S. R., Francos, B., Sharma, S., Falkner, B., McGowan, T. A., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010101049 · Cited by 319
Self-citationProtein kinase C and the development of diabetic vascular complications
Way, K. J., Katai, N., & King, G. L. (2001) · Diabetic Medicine · doi:10.1046/j.0742-3071.2001.00638.x · Cited by 313
Unuofin, J. O., & Lebelo, S. L. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/1356893 · Cited by 308
Targeting renal fibrosis: Mechanisms and drug delivery systems
Nastase, M. V., Zeng-Brouwers, J., Wygrecka, M., & Schaefer, L. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.12.019 · Cited by 302
The role of EMT in renal fibrosis
Carew, R. M., Wang, B., & Kantharidis, P. (2012) · Cell and Tissue Research · doi:10.1007/s00441-011-1227-1 · Cited by 294
Vascular dysfunction in diabetes mellitus
Feener, E. P., & King, G. L. (1997) · The Lancet · doi:10.1016/s0140-6736(97)90022-2 · Cited by 287
Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers
Twigg, S. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1991 · Cited by 286
Kislinger, T., Tanji, N., Wendt, T., Qu, W., Lu, Y., Ferran, L. J., Taguchi, A., Olson, K., Bucciarelli, L., Goova, M., et al. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.6.905 · Cited by 285
A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy
Lee, M.-J., Feliers, D., Mariappan, M. M., Sataranatarajan, K., Mahimainathan, L., Musi, N., Foretz, M., Viollet, B., Weinberg, J. M., Choudhury, G. G., et al. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00278.2006 · Cited by 285
Suthanthiran, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050420897 · Cited by 281
Ishii, H., Koya, D., & King, G. L. (1997) · Journal of Molecular Medicine · doi:10.1007/s001090050187 · Cited by 274
Regulation and Physiological Roles of Serum- and Glucocorticoid-Induced Protein Kinase Isoforms
Lang, F., & Cohen, P. (2001) · Science's STKE · doi:10.1126/stke.2001.108.re17 · Cited by 274
Loss of Angiotensin-Converting Enzyme-2 (Ace2) Accelerates Diabetic Kidney Injury
Wong, D. W., Oudit, G. Y., Reich, H., Kassiri, Z., Zhou, J., Liu, Q. C., Backx, P. H., Penninger, J. M., Herzenberg, A. M., & Scholey, J. W. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060977 · Cited by 273
Role of the hexosamine biosynthetic pathway in diabetic nephropathy
Schleicher, E. D., & Weigert, C. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.07703.x · Cited by 271
Mechanisms of diabetic vasculopathy: an overview
Cooper, M. (2001) · American Journal of Hypertension · doi:10.1016/s0895-7061(00)01323-6 · Cited by 267
Microvascular basement membranes in diabetes mellitus
Tsilibary, E. C. (2003) · The Journal of Pathology · doi:10.1002/path.1439 · Cited by 267
TGF-β signaling in the kidney: profibrotic and protective effects
Sureshbabu, A., Muhsin, S. A., & Choi, M. E. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00365.2015 · Cited by 267
Li, J. H., Huang, X. R., Zhu, H., Oldfield, M., Cooper, M., Truong, L. D., Johnson, R. J., & Lan, H. Y. (2004) · The FASEB Journal · doi:10.1096/fj.02-1117fje · Cited by 264
Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease
Jung, C.-Y., & Yoo, T.-H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0329 · Cited by 262
Pathophysiology of the Diabetic Kidney
Vallon, V., & Komers, R. (2011) · Comprehensive Physiology · doi:10.1002/cphy.c100049 · Cited by 259
Chen, S., Jim, B., & Ziyadeh, F. N. (2003) · Seminars in Nephrology · doi:10.1053/s0270-9295(03)00132-3 · Cited by 256
Self-citationNoh, H., Oh, E. Y., Seo, J. Y., Yu, M. R., Kim, Y. O., Ha, H., & Lee, H. B. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00086.2009 · Cited by 254
Hydrogen peroxide increases extracellular matrix mRNA through TGF-β in human mesangial cells
Iglesias-de la Cruz, M. C., Ruiz-Torres, P., Alcamí, J., Díez-Marqués, L., Ortega-Velázquez, R., Chen, S., Rodríguez-Puyol, M., Ziyadeh, F. N., & Rodríguez-Puyol, D. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00469.x · Cited by 217
Self-citationαvβ6 Integrin Regulates Renal Fibrosis and Inflammation in Alport Mouse
Hahm, K., Lukashev, M. E., Luo, Y., Yang, W. J., Dolinski, B. M., Weinreb, P. H., Simon, K. J., Chun Wang, L., Leone, D. R., Lobb, R. R., et al. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060158 · Cited by 190
Essential Role of TGF-β Signaling in Glucose-Induced Cell Hypertrophy
Wu, L., & Derynck, R. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.05.010 · Cited by 167
BAMBI Elimination Enhances Alternative TGF-β Signaling and Glomerular Dysfunction in Diabetic Mice
Fan, Y., Li, X., Xiao, W., Fu, J., Harris, R. C., Lindenmeyer, M., Cohen, C. D., Guillot, N., Baron, M. H., Wang, N., et al. (2015) · Diabetes · doi:10.2337/db14-1397 · Cited by 57
Metadata
- Authors
- Sharma, K., Jin, Y., Guo, J., & Ziyadeh, F. N.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1996-04-01
- Volume
- 45
- Issue
- 4
- Pages
- 522-530
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2061202476
- Cited by
- 662
- References
- 0
- FWCI
- 23.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.